This week on The Pharmcast, we discuss areas often overlooked in due diligence efforts that can lead to expensive or even show-stopper surprises once the acquisition is complete and later development and commercial efforts are underway, with two former Johnson & Johnson medical devices executives, Donna Godward and Dr. Janet Vargo. Understanding what to look for (or present) during due diligence will reduce risks and lead to a better evaluation for the transaction.
This week on The Pharmcast, we explore best practices and common pitfalls in FDA 483 Responses.
In 2015, there were an average of 175 inspections and 10 warning letters issued per month by the Center for Devices and Radiological Health alone. Regulatory inspections and 483 findings are a part of being a life sciences company. However, how companies respond can have a major impact on patient safety and business performance.
To share best practices, we held a special presentation with two of our top medical device experts, Victor Chance and Judy Meritz, to outline what they’ve learned over the course of their 20+ year careers in the medical devices industry.
How has your company been preparing for EU MDR?
Minnie Baylor-Henry and Jon Lange discussed this topic during one of our most well attended webinars last month. If you missed the live event, you can now watch the recorded presentation below.